Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Update

Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 7,090,000 shares, a growth of 5.3% from the February 13th total of 6,730,000 shares. Based on an average daily volume of 821,900 shares, the days-to-cover ratio is currently 8.6 days. Approximately 11.0% of the company’s shares are sold short.

Insider Buying and Selling

In other news, COO Kathleen Ford sold 1,821 shares of the business’s stock in a transaction that occurred on Friday, January 27th. The stock was sold at an average price of $13.89, for a total value of $25,293.69. Following the transaction, the chief operating officer now owns 21,214 shares of the company’s stock, valued at $294,662.46. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, COO Kathleen Ford sold 1,821 shares of the company’s stock in a transaction on Friday, January 27th. The stock was sold at an average price of $13.89, for a total value of $25,293.69. Following the completion of the transaction, the chief operating officer now directly owns 21,214 shares in the company, valued at $294,662.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kirsten Flowers sold 1,906 shares of the company’s stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $13.89, for a total value of $26,474.34. Following the sale, the insider now owns 20,605 shares of the company’s stock, valued at $286,203.45. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,275 shares of company stock valued at $73,270. 5.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Great West Life Assurance Co. Can bought a new position in Kura Oncology in the 3rd quarter worth approximately $39,000. Point72 Middle East FZE bought a new position in Kura Oncology in the 4th quarter worth approximately $115,000. Gyon Technologies Capital Management LP bought a new stake in shares of Kura Oncology during the 4th quarter valued at $119,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Kura Oncology by 38.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,596 shares of the company’s stock valued at $119,000 after acquiring an additional 2,650 shares during the last quarter. Finally, Annandale Capital LLC bought a new stake in shares of Kura Oncology during the 3rd quarter valued at $137,000.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Stifel Nicolaus initiated coverage on Kura Oncology in a report on Monday, January 30th. They set a “buy” rating and a $25.00 target price on the stock. StockNews.com began coverage on Kura Oncology in a research report on Thursday. They issued a “sell” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Friday, February 24th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average price target of $31.20.

Kura Oncology Stock Up 0.5 %

NASDAQ KURA opened at $11.75 on Friday. The company has a current ratio of 18.56, a quick ratio of 18.56 and a debt-to-equity ratio of 0.02. The stock’s 50 day moving average is $12.61 and its two-hundred day moving average is $13.66. The company has a market capitalization of $804.17 million, a price-to-earnings ratio of -5.79 and a beta of 0.93. Kura Oncology has a 1-year low of $10.30 and a 1-year high of $19.93.

Kura Oncology (NASDAQ:KURA – Get Rating) last announced its earnings results on Thursday, February 23rd. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.09. Equities analysts forecast that Kura Oncology will post -2.38 earnings per share for the current fiscal year.

Kura Oncology Company Profile

(Get Rating)

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.